Document is current
Any future updates will be listed below
-
Authors
Nekoufar, Samira
Ghorbani, Marjan
Safaei, Sahar
Khosroushahi, Gholamreza Alinezhadi
Shirian, Farzad Izak
Baradaran, Behzad https://orcid.org/0000-0002-8642-6795
Tavakoli-Yaraki, Masoumeh https://orcid.org/0000-0003-4449-9248
-
Funding
Funding for this research was provided by:
Iran University of Medical Sciences (1401-1-4-22282, 1401-1-4-22282, 1401-1-4-22282, 1401-1-4-22282, 1401-1-4-22282, 1401-1-4-22282, 1401-1-4-22282)
- License Information
-
More Information
Article History
Received: 30 August 2024
Accepted: 25 December 2024
First Online: 9 January 2025
Declarations
:
: The project underwent an ethical evaluation and received approval from the ethics committee of the Vice President of Research at Iran University of Medical Sciences. The project code assigned by the ethics committee is IR.IUMS.FMD.REC.1401.206. The project solely utilized a commercially available cell line, specifically the MIA-PaCa-2 cells, which were procured from the cell stock center and possess an authentic certificate. As a result, there was no requirement to obtain consent from any patients. This research involved in vitro experimentation using commercially purchased cells from a cell bank, and did not involve any human samples or data from patients or healthy subjects. Therefore, no “participant consent” was required.
: Since the manuscript and supplementary materials do not contain any personal or identifying information of participants, the consent for publication is unnecessary.
: The authors declare no competing interests.
